Related Experiment Video

Updated: Dec 24, 2025

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts
11:19

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts

Published on: October 9, 2016

15.4K

Targeting STAT3 in cancer and autoimmune diseases

Tohid Gharibi1, Zohreh Babaloo2, Arezoo Hosseini1

  • 1Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Department of Immunology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran; Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran; Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran.

European Journal of Pharmacology
|April 13, 2020
PubMed

Insights

Signal transducer and activator of transcription 3 (STAT3) is crucial in cancer and autoimmune diseases. Small molecules targeting STAT3 show therapeutic potential for these conditions in preclinical and clinical studies.

Area of Science:

  • Molecular Biology
  • Immunology
  • Oncology

Background:

  • Signal transducer and activator of transcription 3 (STAT3) is a key transcription factor involved in cell proliferation, survival, and apoptosis.
  • Constitutive activation of STAT3 is observed in many human cancers, highlighting its role in tumor progression.
  • STAT3 also plays significant roles in lymphocyte function, immune responses, and the development of autoimmune diseases.

Purpose of the Study:

  • To review the critical role of STAT3 in cancer and autoimmune diseases.
  • To discuss the efficacy and therapeutic potential of STAT3 inhibitors.
  • To provide insights into novel approaches for developing new STAT3 inhibitors.

Main Methods:

  • Literature review of preclinical studies and clinical trials.
  • Analysis of STAT3's function in cancer and autoimmune disease models.
  • Evaluation of small molecule inhibitors targeting STAT3.

Main Results:

  • STAT3 is a significant driver of tumor progression and a key factor in autoimmune disorders.
  • Various small molecules targeting STAT3 have demonstrated therapeutic efficacy in preclinical settings.
  • Clinical trials are exploring the potential of STAT3 inhibitors for treating cancer and autoimmune diseases.

Conclusions:

  • STAT3 is a promising therapeutic target for both cancer and autoimmune diseases.
  • Development of STAT3 inhibitors is an active area of research with significant clinical implications.
  • Further investigation into novel STAT3 inhibitors may offer new treatment strategies.
Keywords:
Autoimmune diseasesCancerSTAT3Small molecule inhibitors

More Related Videos

Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome07:23

Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome

Published on: June 15, 2016

8.8K
Skeletal Phenotype Analysis of a Conditional Stat3 Deletion Mouse Model08:42

Skeletal Phenotype Analysis of a Conditional Stat3 Deletion Mouse Model

Published on: July 3, 2020

4.9K

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
11.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.7K